Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 29 for “"Lapatinib"”.
-
Understanding Acquired Resistance to Lapatinib In Breast Cancer Cells
… often over-expressed in human breast carcinomas. Lapatinib is an ErbB1 and ErbB2 tyrosine kinase inhibitor that has been shown to have anti-proliferative effects in breast and lung cancer cells. Cells treated with Lapatinib undergo G1 phase arrest, followed by apoptosis. Lapatinib has been …
-
Measuring Single Cell Responses to Lapatinib In A Heterogeneous Population
… to anti- EGFR/ErbB2 therapy in breast cancer to Lapatinib [1]. However, one the of the very important unanswered questions at the cellular and molecular level is the mechanismsthatleadstoselection of cells that are resistant to Lapatinib whereby there exists two possibilities: 1. Cells are …
-
Pi3K- and Mtor-Dependent Mechanisms of Lapatinib Resistance and Resulting Therapeutic Opportunities
… responsive to the HER2 kinase inhibitor lapatinib, but generally for only short duration. We aimed to understand how breast cancers with HER2 amplification become resistant to lapatinib, in order to identify potential therapies that can overcome lapatinib resistance. To establish …
-
An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors
… therapy with the tyrosine kinase inhibitor (TKI) lapatinib, in vitro, and elucidation of the ensuing conformational changes may help understand the molecular activity of lapatinib and elucidate mechanisms of resistance. Clinical translation of this knowledge may help to improve performance of …
-
Pharmacological modulation and manipulation of cancer drug resistance
… pre-treated proliferation assays. Three agents (lapatinib, sulindac sulphide and 17-AAG) reduced the expression of MRP1 in the A549 cell line. Only sulindac sulphide overcame MRP1-mediated resistance in the combination proliferations assays; however, this was due to the inhibitory mechanism of …
-
The role of ErbB inhibitors in promoting nerve regeneration in a mouse model of nerve injury
… whether the dual ErbB1-ErbB2 inhibitor lapatinib or the ErbB1 inhibitor gefitinib could promote nerve regeneration in both in vivo and in vitro models. Using a mouse transection and repair sciatic nerve injury model, lapatinib was found to increase the number of regenerated myelinated …
-
Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines
… inhibitors (TKIs), gefitinib, erlotinib and lapatinib, to circumvent resistance to docetaxel, and other chemotherapeutic agents, arising from P-gp over-expression. A HPLC – based method was initially employed to quantify docetaxel levels in cells. The very high taxane levels required rendered …
-
Characterisation and modulation of drug resistance in lung cancer cell lines
… and to increase our knowledge of the effect of lapatinib, a newly developed targeted therapy, in these resistant cells. Lapatinib, a growth factor receptor tyrosine kinase inhibitor synergised with P-gp substrate cytotoxics in P-gp over-expressing resistant cells. However, lapatinib treatment, …
-
The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer
… SKBR3 cells. SKBR3 cells were conditioned in lapatinib (a dual HER-2/EGFR TKI), and the conditioned SKBR3-L cells showed significantly reduced response to lapatinib, and to Tmab, compared to parental SKBR3 cells. Phosphoproteomic analysis revealed alterations in the levels of a number of …
-
Novel Role of ErbB-2 in Inhibition of Jagged-1-Mediated Trans-Activation of Notch in Breast Cancer
… against the extracellular domain of ErbB-2 and lapatinib, a dual EGFR/ErbB-2 tyrosine kinase inhibitor. Unfortunately, anti-ErbB-2 therapy resistance remains a major problem in metastatic breast cancer. Our data suggested that gene amplification or overexpression of ErbB-2 inhibits Notch-1 …
-
Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos.
… TKIs administrados (erlotinib, imatinib, lapatinib, pazopanib, sorafenib y sunitinib) y las consecuentes modificaciones de dosis realizadas. Material y método: estudio analítico retrospectivo en el que se han incluido 74 pacientes en tratamiento con TKIs, a los que se les ha realizado TDM …
-
Molecular mechanisms of drug resistance, invasion and metastasis in pancreatic carcinoma
… co-expressed EGFR and HER2 were tested with lapatinib. Lapatinib, a dual EGFR/HER2 inhibitor in combination with chemotherapeutic drugs showed additive interactions, suggesting the possibility of a therapeutic role for lapatinib in combination with chemotherapy in pancreatic cancer patients …
-
RNA Interference for Improving the Outcome of Islet Transplantation and Polymeric Micelle‑based Nanomedicine for Cancer Therapy
… Chapter 7, we studied the use of paclitaxel and lapatinib loaded lipopolymer micelles for treating MDR prostate cancers. Although paclitaxel remains effective in treating prostate cancer, its prolonged treatment develops MDR due to the over‑expression of P‑gp. Our hypothesis is that combination …
-
The Dendritic Cell Response to Exogenous and Endogenous Danger Signals
… nephritis. To test this possibility we used lapatinib, an EGFR-ErbB2 dual kinase inhibitor, in an IFN-accelerated model of murine lupus. We found that lapatinib administration lowered autoantibody levels but worsened renal disease. Lapatinib failure to treat murine lupus nephritis despite …
-
Chemoprevention of Lung Carcinogenesis: Aerosol Administration and Deposition in the Mouse Lung
… molecular inhibitors: gefitinib, erlotinib, lapatinib and wortmannin), and four natural agents: resveratrol, caffeine, anthocyanins, and protocatechuic acid), were considered as examples of single agents. Gefitinib and erlotinib were delivered in an aerosol form to reduce the cutaneous side …
-
Role of X-Linked Inhibitor of Apoptosis Protein in Therapeutic Resistance of Inflammatory Breast Cancer Cells
… using trastuzumab (anti-ErbB2 antibody) and lapatinib (small molecule ErbB1/2 inhibitor). However, acquired resistance is a common outcome even in IBC patients who show an initial clinical response, which limits the efficacy of these agents. Little is known about the molecular mechanisms of …
-
Integrin-Mediated Mechanotransduction Controls Activation of Yap and Invasive Growth of Breast Cancer
… administration of Dasatinib combined with Lapatinib significantly increases the efficacy of HER2 inhibition in the MMTV-Neu mouse model of HER2+ breast cancer. These findings reveal a major mechanism through which the Hippo tumor suppressive pathway is disabled in breast cancer and suggest …
-
Analysis of Out-of-Pocket Expenditures of Oral Oncologics for Tennessee Recipients of Medicare Part D
… dasatinib, sunitinib, vorinostat, nilotinib, and lapatinib, the annual out-of-pocket costs for each drug varied from $0 to a maximum of $1,133, based on plan design. Bivariate regression analysis showed that monthly premiums, deductibles, and cost-sharing are all precise predictors of …
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
… rendering them susceptible to sapatinib- and lapatinib-induced cell death. Further, increased autophagic flux was seen in all progressive tumours on sapatinib. The increased resistance to sapatinib in mice fed an iron-deficient diet was also associated with increased autophagic flux, although …
-
Inhibition of the endosomal recycling pathway to overcome resistance to cancer therapies
… monensin, drug resistance, tamoxifen, lapatinib, enzalutamide, synergy.
Page 1 of 2